XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo
This article was originally published in The Pink Sheet Daily
Executive Summary
Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.
You may also be interested in...
FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK
The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.
FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK
The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.
Battered XenoPort Holds On For April PDUFA Date For Horizant
XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.